Eli Lilly Strengthens Its Weight Loss Pipeline. Why Retatrutide Could Be the Next Growth Driver for LLY – R Blog – RoboForex
On Monday, June 8, LLY shares opened with a 2.5% gap up following the release of full Phase 3 clinical trial results for Retatrutide. This experimental weight loss drug could become Eli Lilly‘s next major product after Mounjaro and Zepbound — and the data are significantly stronger than anything seen from rivals. In Brief Average…